Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.

Drugs
Sean T Duggan

Abstract

Pitavastatin (Livazo®, Livalo®), an inhibitor of HMG-CoA reductase (statin), is indicated for the reduction of elevated total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels, in adult patients with primary hypercholesterolaemia and mixed dyslipidaemia, when response to diet and other non-pharmacological measures is inadequate. Pitavastatin has a favourable pharmacological profile following oral administration, including its long half-life (up to 12 hours), selective uptake into hepatocytes and minimal metabolism by cytochrome P450 (CYP) enzymes. This latter property decreases the likelihood of drug-drug interactions with agents that are metabolized by, inhibit or induce CYP enzymes. Pitavastatin improved the lipid profile (including LDL-C, TC and high-density lipoprotein cholesterol levels) in patients with hypercholesterolaemia and mixed dyslipidaemia, according to large, pivotal phase III studies of up to 60 weeks' duration. In these trials, pitavastatin for 12 weeks was noninferior to simvastatin and atorvastatin in terms of the improvement from baseline in LDL-C levels. In similarly designed trials, pitavastatin improved lipid profiles and was noninferior to simvastatin in patients with high cardiova...Continue Reading

References

May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Sep 15, 2001·Bioorganic & Medicinal Chemistry·M SuzukiR Sakoda
Jan 10, 2003·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·H FujinoJ Kojima
May 13, 2003·Journal of Atherosclerosis and Thrombosis·Hideo SuzukiKatsuo Sueishi
Aug 26, 2003·Journal of Cellular Biochemistry·Ronald A MarkleAndrew C Nicholson
May 22, 2004·Journal of Atherosclerosis and Thrombosis·Shigeru MorikawaTatsuhiko Kodama
May 26, 2004·The Journal of Pharmacology and Experimental Therapeutics·Masaru HiranoYuichi Sugiyama
Oct 12, 2004·Biochemical and Biophysical Research Communications·Takashi MaejimaY Saito
Dec 14, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Akio KawakamiMasayuki Yoshida
Dec 25, 2004·Drug Metabolism and Pharmacokinetics·Syunsuke ShimadaJunji Kojima
Mar 9, 2005·British Journal of Clinical Pharmacology·C K HuiG K K Lau
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Jae-Yong ChungIn-Jin Jang
Oct 21, 2005·British Journal of Clinical Pharmacology·Hitoshi AndoAkio Fujimura
May 31, 2006·Journal of Atherosclerosis and Thrombosis·Yuji YoshitomiAtsuyoshi Miyauchi
Nov 6, 2007·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Ian GrahamUNKNOWN European Atherosclerosis Society (EAS)
Oct 30, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroaki TakashimaTakayuki Ito
Mar 26, 2008·Circulation Journal : Official Journal of the Japanese Circulation Society·Yukio MizuguchiTakashi Oki
Apr 23, 2008·Journal of Cardiovascular Pharmacology·Takamitsu NakamuraKiyotaka Kugiyama
Dec 17, 2008·Journal of Atherosclerosis and Thrombosis·Hiroyuki KoshiyamaUNKNOWN Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology Investigators
Feb 4, 2009·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Rishi SukhijaJawahar L Mehta
Jun 16, 2009·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Shosaku NomuraToshiji Iwasaka
Jun 18, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Toru ToiNoboru Kaneko
Jun 18, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Kenshiro AraoShin-Ichi Momomura

❮ Previous
Next ❯

Citations

Oct 28, 2014·The FEBS Journal·Swagatika SahooInes Thiele
Jun 11, 2015·The Journal of Pediatrics·Marjet J A M BraamskampUNKNOWN PASCAL Study Group
Feb 5, 2015·Journal of Clinical Pharmacology·Merle MyersonJudith A Aberg
Nov 16, 2014·Current Atherosclerosis Reports·Nishant P ShahSeth S Martin
Jan 29, 2017·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Sheridan M Hoy
Jan 16, 2018·Expert Opinion on Pharmacotherapy·Niki KatsikiAmirhossein Sahebkar

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.